EGFR and lung carcinoma: Mutations in epidermal growth factor receptor (EGFR) occur in approximately 20% cases of lung cancer [4], and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are indispensable in the treatment of EGFR-mutant advanced LUAD.